Exploring treatment and molecular markers in recurrent colorectal cancer
Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer
This study looks at the medical records of patients with recurrent colorectal cancer to see how different treatments, especially surgery, affect their survival and to find markers that might help understand the disease better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06114420 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes the medical records of patients with locally recurrent colorectal cancer (LRCRC) who were hospitalized at our center. It aims to investigate the clinicopathological characteristics and survival outcomes associated with different treatment modalities, particularly focusing on surgical interventions. Additionally, the study employs transcriptome sequencing and public databases to identify molecular markers that may influence the progression of LRCRC. By understanding these factors, the study seeks to enhance treatment strategies for affected patients.
Who should consider this trial
Good fit: Ideal candidates include patients with locally recurrent colorectal cancer who have undergone radical surgery for stage II-III colorectal cancer and have complete medical records.
Not a fit: Patients with familial hereditary colorectal cancer, other malignant tumors, or recent peritoneal recurrence may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better survival outcomes for patients with locally recurrent colorectal cancer.
How similar studies have performed: While there have been studies on surgical treatments for colorectal cancer, this study's specific focus on molecular markers in recurrent cases is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with LRCRC who received hospitalization in our center and patients with stage II-III colorectal cancer whose primary surgery was radical surgery 2. The pathological type of primary tumor is adenocarcinoma 3. Postoperative local recurrence of colorectal cancer diagnosed by imaging or pathological examination 4. Have complete medical records and continuous follow-up records Exclusion Criteria: 1. Familial hereditary colorectal malignant tumors 2. Past history of other malignant tumors 3. Recurrence and diffuse peritoneal recurrence occurring within 1 month after surgery
Where this trial is running
Beijing, Beijing
- Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Fei Huang, M.D.
- Email: frankhuangxm@outlook.com
- Phone: 86-010-87787670
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.